(0.14%) 5 113.50 points
(-0.04%) 38 709 points
(0.55%) 17 704 points
(-0.46%) $82.98
(-0.33%) $1.806
(-0.49%) $2 330.60
(-0.57%) $27.21
(0.10%) $923.70
(0.12%) $0.935
(0.46%) $10.95
(0.11%) $0.804
(-0.87%) $92.38
Live Chart Being Loaded With Signals
Hua Medicine (Shanghai) Ltd. operates as a clinical-stage drug development company that focuses on therapies for the treatment of diabetes in China. It develops Dorzagliatin or HMS5552, an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin that is in Phase I clinical trial for treatment of T2D...
Stats | |
---|---|
Today's Volume | 1.24M |
Average Volume | 1.05M |
Market Cap | 1.56B |
EPS | HKD0 ( 2024-03-27 ) |
Last Dividend | HKD0 ( N/A ) |
Next Dividend | HKD0 ( N/A ) |
P/E | -6.63 |
ATR14 | HKD0.0170 (1.07%) |
Hua Medicine Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Hua Medicine Financials
Annual | 2023 |
Revenue: | HKD76.61M |
Gross Profit: | HKD37.37M (48.78 %) |
EPS: | HKD-0.220 |
Q2 | 2023 |
Revenue: | HKD35.17M |
Gross Profit: | HKD22.02M (62.63 %) |
EPS: | HKD-0.0463 |
Q1 | 2023 |
Revenue: | HKD35.17M |
Gross Profit: | HKD22.02M (62.63 %) |
EPS: | HKD-0.0463 |
Q4 | 2022 |
Revenue: | HKD184 000 |
Gross Profit: | HKD-4.77M (-2 592.93 %) |
EPS: | HKD-0.0507 |
Financial Reports:
No articles found.
Hua Medicine
Hua Medicine (Shanghai) Ltd. operates as a clinical-stage drug development company that focuses on therapies for the treatment of diabetes in China. It develops Dorzagliatin or HMS5552, an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin that is in Phase I clinical trial for treatment of T2D. The company also offers Dorzagliatin in combination with Pioglitazone for NASH; in combination with GLP-1 for Alzheimer diseases; and in combination with late stage T2D and Type 1 Diabetes. In addition, it is developing mGLUR5 for the treatment of Parkinson's disease levodopa-induced dyskinesia. The company was incorporated in 2011 and is based in Beijing, China.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators